Boston Scientific released the full $8 million holdback on schedule and with no claims; Escrow release is the third funding catalyst Elutia has delivered in 2026, following the Au ...
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) ...
Nutraville is expanding its healthy-aging portfolio with Pineal Guardian Advanced, a liquid botanical formula that combines 11 nutritional and plant-based ingredients to support pineal gland wellness, ...
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock. DALLA ...
A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug ...
Major shareholder announcement . Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational chang ...
One year after relocating from Oak Park and nearly tripling its floor space, the specialty practice has opened a dedicated center for severe dry eye alongside two stations for teaching patients to ...
IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with ...
Bloom Healthcare, a passionate team of medical providers specializing in in-home primary care for seniors with complex health needs, today announced its expansion into the Dallas-Fort Worth (DFW) ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing ...
Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results